Business Description
Akari Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00972G1085
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.05 | |||||
Debt-to-EBITDA | N/A | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32.9 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 32.1 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 73.57 | |||||
9-Day RSI | 65.62 | |||||
14-Day RSI | 58.75 | |||||
6-1 Month Momentum % | -64.38 | |||||
12-1 Month Momentum % | -64.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.95 | |||||
Quick Ratio | 0.95 | |||||
Cash Ratio | 0.84 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -51 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History |
---|
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | N/A | |||||
PE Ratio without NRI | N/A | |||||
EV-to-EBIT | -0.53 | |||||
EV-to-EBITDA | -0.53 | |||||
EV-to-FCF | -0.54 | |||||
Earnings Yield (Greenblatt) % | -188.68 | |||||
FCF Yield % | -129.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Akari Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | 0 | ||
Beta | 0.37 | ||
Volatility % | 62.09 | ||
14-Day RSI | 58.75 | ||
14-Day ATR (€) | 0.086315 | ||
20-Day SMA (€) | 1.12225 | ||
12-1 Month Momentum % | -64.81 | ||
52-Week Range (€) | 0.945 - 4.64 | ||
Shares Outstanding (Mil) | 7.92 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Akari Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Akari Therapeutics PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Akari Therapeutics PLC Frequently Asked Questions
What is Akari Therapeutics PLC(FRA:CLA)'s stock price today?
When is next earnings date of Akari Therapeutics PLC(FRA:CLA)?
Does Akari Therapeutics PLC(FRA:CLA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |